Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMK1ZOR)

Drug Name
Vincamine Drug Info
Synonyms
vincamine; 1617-90-9; Pervincamine; Devincan; Minorine; Vincamidol; Novicet; Monorin; Methyl vincaminate; Arteriovinca; Vincasaunier; Vinkametrin; Devinkan; Decincan; Vincapront; Vincafolina; Vincadar; Tripervan; Angiopac; Anasclerol; (+)-Vincamine; Equipur; Pervone; Oxygeron; Vincafor; Perval; Ocu-vinc; Vincamina [DCIT]; Vincimax; Vincamine base; Vincaminum [INN-Latin]; UNII-996XVD0JHT; Vincamine [INN:BAN:DCF]; Minorin; Vincachron; Vincapan; Vincamin; Vincagil; Vinca; Vinodrel retard; Vinca-Minor; Vinca-Ecobi; HSDB 7150; Anasclerol (base)
Cross-matching ID
PubChem CID
15376
ChEBI ID
CHEMBL9985
CAS Number
CAS 1617-90-9
TTD Drug ID
D08UGJ
VARIDT Drug ID
DR01180
INTEDE Drug ID
DR1690

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Huntington disease -1.68 3.02e-2 233/306 (76.14%) ATG2A;NDUFA4;PSMB6;...
Cholesterol metabolism -1.69 2.98e-2 44/50 (88%) APOC3;SOAT2;SORT1;...
Proteasome -1.70 2.83e-2 44/46 (95.65%) PSMB6;PSMA5;PSMD1;...
Protein export -1.70 2.93e-2 17/23 (73.91%) SRPRA;SEC61B;SRPRB;...
Ribosome -1.72 2.72e-2 113/158 (71.52%) RPS21;RPL23A;RPL21;...
Amoebiasis -1.72 2.82e-2 99/102 (97.06%) PLCB2;LAMA4;RAB5A;...
VEGF signaling pathway -1.72 2.88e-2 50/59 (84.75%) NRAS;RAF1;MAP2K2;...
Viral myocarditis -1.72 2.88e-2 53/60 (88.33%) EIF4G1;HLA-A;HLA-F;...
NF-kappa B signaling pathway -1.73 3.01e-2 90/104 (86.54%) TICAM1;PLCG1;RELA;...
Staphylococcus aureus infection -1.76 2.40e-2 72/95 (75.79%) FPR1;C5AR1;HLA-DPB1;...
Systemic lupus erythematosus -1.80 1.44e-2 45/135 (33.33%) SNRPD3;SNRPB;HLA-DPB1;...
Galactose metabolism -1.81 1.36e-2 26/31 (83.87%) HK3;PGM1;GAA;...
Protein processing in endoplasmic reticulum -1.81 1.44e-2 127/171 (74.27%) SSR1;BAK1;MAN1B1;...
Citrate cycle (TCA cycle) -1.81 1.52e-2 30/30 (100%) MDH2;SUCLA2;IDH3G;...
Phagosome -1.81 1.35e-2 118/152 (77.63%) COMP;CTSS;SEC61B;...
Legionellosis -1.82 1.44e-2 51/57 (89.47%) SAR1B;ARF1;CYCS;...
Fructose and mannose metabolism -1.83 1.44e-2 30/33 (90.91%) PFKFB2;TKFC;SORD;...
Bladder cancer -1.83 1.55e-2 40/41 (97.56%) NRAS;RAF1;MMP9;...
Fatty acid biosynthesis -1.85 1.32e-2 16/18 (88.89%) ACSBG2;CBR4;OXSM;...
Other glycan degradation -1.86 1.44e-2 13/18 (72.22%) ENGASE;HEXB;MAN2C1;...
Asthma -1.86 1.58e-2 25/31 (80.65%) HLA-DPB1;FCER1G;PRG2;...
Allograft rejection -1.88 1.44e-2 32/38 (84.21%) HLA-DPB1;IFNG;HLA-B;...
Glycolysis / Gluconeogenesis -1.94 5.40e-3 56/67 (83.58%) ADH1C;ADH1A;ADH6;...
Type I diabetes mellitus -1.97 4.11e-3 38/43 (88.37%) CD86;FAS;ICA1;...
Graft-versus-host disease -2.00 2.40e-3 32/42 (76.19%) HLA-DPB1;IFNG;HLA-B;...
Pentose phosphate pathway -2.01 2.88e-3 25/30 (83.33%) ALDOC;RBKS;DERA;...
Antigen processing and presentation -2.06 0.00e+0 60/78 (76.92%) HSPA2;CTSS;HLA-DPB1;...
Epithelial cell signaling in Helicobacter pylori infect... -2.12 0.00e+0 62/70 (88.57%) HBEGF;MAPK14;TJP1;...
Rheumatoid arthritis -2.16 0.00e+0 78/93 (83.87%) MMP1;ATP6V0E1;HLA-DPB1;...
IL-17 signaling pathway -2.29 0.00e+0 84/94 (89.36%) ANAPC5;MAPK3;MAPK14;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H